SCHEMBL1632209

SCHEMBL1632209

NC(=O)C(c1cccnc1)c1ccc(-c2ccccc2F)nc1NCCc1ccccn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
POLB P06746 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
GBA1 P04062 1/20 0.39
ADORA2A P29274 2/20 0.39
ADORA1 P30542 2/20 0.39
JAK3 P52333 1/20 0.39
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
HTR2C P28335 1/20 0.34
HTR7 P34969 1/20 0.34
PIM1 P11309 3/20 0.34
PIM3 Q86V86 3/20 0.34
PIM2 Q9P1W9 3/20 0.34
NPC1 O15118 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1629838 0.91 GBA1 (0.40) ALDH1A1MEN1KMT2AGBA1JAK3
SCHEMBL1631782 0.90 SMN1; SMN2 (0.43) MEN1KMT2AKDM4EGBA1ADORA2A
SCHEMBL1631308 0.90 GBA1 (0.39) ALDH1A1MEN1KMT2AKDM4EGBA1
SCHEMBL1629987 0.88 GBA1 (0.38) ALDH1A1MEN1KMT2AKDM4EGBA1
SCHEMBL1631004 0.88 GBA1 (0.43) GBA1JAK3HDAC2SMN1; SMN2HTR2C
SCHEMBL1630995 0.88 GBA1 (0.48) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL1632665 0.88 PGK1 (0.41) ALDH1A1KDM4EHSD17B10GBA1ADORA2A
SCHEMBL1631871 0.88 GBA1 (0.40) MEN1KMT2AKDM4EHPGDGBA1
SCHEMBL1631138 0.88 PIK3CD (0.39) ALDH1A1KDM4EGBA1ADORA2AADORA1
SCHEMBL1630502 0.88 ADORA2A (0.41) ALDH1A1MEN1KMT2APOLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 US claimed
US-7932270-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2011-04-26 US disclosed
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012126-A1 Certain chemical entities, compositions, and methods MYLK, MYH2, MYH10 ALDH1A1 1756/4885MEN1 510/4885KMT2A 2544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.